Toxicity assessments of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes

Toxicology and Applied Pharmacology

Volumn 272, Issue 2, 2013, Pages 272-280

  Nadanaciva, Sashi ^a   Aleo, Michael D ^a   Strock, Christopher J ^b   Stedman, Donald B ^a   Wang, Huijun ^a   Will, Yvonne ^a  

^a PFIZER INC   (United States)

^b CYPROTEX DISCOVERY LTD   (United Kingdom)

Author keywords

High content imaging; Liver toxicity; Mitochondrial toxicity; NSAIDS (non steroidal anti inflammatories); Zebrafish

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; DIFLUNISAL; FLUFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SUDOXICAM; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; TOLFENAMIC ACID;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR RISK; CELL ISOLATION; CELL RESPIRATION; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG CYTOTOXICITY; DRUG EFFECT; EMBRYO; ENDOPLASMIC RETICULUM STRESS; FEMALE; LIVER CELL; LIVER MITOCHONDRION; LIVER TOXICITY; MALE; MITOCHONDRIAL TOXICITY; MORPHOLOGY; NONHUMAN; RAT; ZEBRA FISH;

AC(50); ADVERSE EVENT REPORTING SYSTEM; AERS; COX; CYCLOOXYGENASE; ENDOPLASMIC RETICULUM; ER; GASTROINTESTINAL; GI; HALF-MAXIMAL ACTIVITY CONCENTRATION; HIGH CONTENT IMAGING; IC(50); LIVER TOXICITY; LOEC; LOWEST OBSERVED EFFECT CONCENTRATION; MITOCHONDRIAL TOXICITY; NO OBSERVED EFFECT CONCENTRATION; NOEC; NONSTEROIDAL ANTI-INFLAMMATORY DRUG; NSAID; NSAIDS (NON-STEROIDAL ANTI-INFLAMMATORIES); REPORTING ODDS RATIO; ROR; THE CONCENTRATION AT WHICH 50% INHIBITION OCCURRED IN STATE 3 RESPIRATION; THE CONCENTRATION AT WHICH 50% UNCOUPLING OCCURRED IN STATE 2 RESPIRATION; UC(50); ZEBRAFISH;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL SURVIVAL; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; EMBRYO, NONMAMMALIAN; HEPATOCYTES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, LIVER; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OXYGEN CONSUMPTION; PRIMARY CELL CULTURE; RATS; TOXICITY TESTS; ZEBRAFISH;

EID: 84883807669     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.06.019     Document Type: Article

References (42)

1. Aithal G.P., Day C.P. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin. Liver Dis. 2007, 11:563-575. (vi-vii).
2. Banks A.T., Zimmerman H.J., Ishak K.G., Harter J.G. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995, 22:820-827.
3. Berry M.N., Edwards A.M., Barritt G.J. Isolated Hepatocytes: Preparation, Properties and Applications 1991, Elsevier, Amsterdam, New York, Oxford.
4. Boelsterli U.A. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf. 2002, 25:633-648.
5. Boelsterli U.A., Redinbo M.R., Saitta K.S. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol. Sci. 2013, 131:654-667.
6. Chitturi S., George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin. Liver Dis. 2002, 22:169-183.
7. Conaghan P.G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol. Int. 2012, 32:1491-1502.
8. Cosgrove B.D., King B.M., Hasan M.A., Alexopoulos L.G., Farazi P.A., Hendriks B.S., Griffith L.G., Sorger P.K., Tidor B., Xu J.J., Lauffenburger D.A. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. 2009, 237:317-330.
9. Duthie A., Nicholls A., Freeth M., Moorhead P., Triger D. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br. Med. J. (Clin. Res. Ed) 1982, 285:62.
10. Dykens J.A., Marroquin L.D., Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 2007, 7:161-175.
11. Gibb S. Toxicity testing in the 21st century: a vision and a strategy. Reprod. Toxicol. 2008, 25:136-138.
12. Greaves P., Williams A., Eve M. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discov. 2004, 3:226-236.
13. Hill A., Mesens N., Steemans M., Xu J.J., Aleo M.D. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab. Rev. 2012, 44:127-140.
14. Hunter E.B., Johnston P.E., Tanner G., Pinson C.W., Awad J.A. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am. J. Gastroenterol. 1999, 94:2299-2301.
15. Hynes J., Marroquin L.D., Ogurtsov V.I., Christiansen K.N., Stevens G.J., Papkovsky D.B., Will Y. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol. Sci. 2006, 92:186-200.
16. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
17. Lewis J.H. Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin. Pharm. 1984, 3:128-138.
18. LoGuidice A., Ramirez-Alcantara V., Proli A., Gavillet B., Boelsterli U.A. Pharmacologic targeting or genetic deletion of mitochondrial cyclophilin D protects from NSAID-induced small intestinal ulceration in mice. Toxicol. Sci. 2010, 118:276-285.
19. Lu S., Jessen B., Strock C., Will Y. The contribution of physicochemical properties to multiple in vitro cytotoxicity endpoints. Toxicol. In Vitro 2012, 26:613-620.
20. McDougall P., Markham A., Cameron I., Sweetman A.J. The mechanism of inhibition of mitochondrial oxidative phosphorylation by the nonsteroidal anti-inflammatory agent diflunisal. Biochem. Pharmacol. 1983, 32:2595-2598.
21. McGrath P., Li C.Q. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov. Today 2008, 13:394-401.
22. Moreno-Sanchez R., Bravo C., Vasquez C., Ayala G., Silveira L.H., Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem. Pharmacol. 1999, 57:743-752.
23. Morgan R.E., Trauner M., van Staden C.J., Lee P.H., Ramachandran B., Eschenberg M., Afshari C.A., Qualls C.W., Lightfoot-Dunn R., Hamadeh H.K. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 2010, 118:485-500.
24. National Research Council Toxicity Testing in the 21st Century 2007, National Academies Press, Washington, DC.
25. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
26. O'Connor N., Dargan P.I., Jones A.L. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM 2003, 96:787-791.
27. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
28. Panzica-Kelly J.M., Zhang C.X., Danberry T.L., Flood A., DeLan J.W., Brannen K.C., Augustine-Rauch K.A. Morphological score assignment guidelines for the dechorionated zebrafish teratogenicity assay. Birth Defects Res. B Dev. Reprod. Toxicol. 2010, 89:382-395.
29. Peters T.S. Do preclinical testing strategies help predict human hepatotoxic potentials?. Toxicol. Pathol. 2005, 33:146-154.
30. Porceddu M., Buron N., Roussel C., Labbe G., Fromenty B., Borgne-Sanchez A. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol. Sci. 2012, 129:332-345.
31. Rubenstein J.H., Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther. 2004, 20:373-380.
32. Shih J., Fraser S.E. Characterizing the zebrafish organizer: microsurgical analysis at the early-shield stage. Development 1996, 122:1313-1322.
33. Somasundaram S., Rafi S., Hayllar J., Sigthorsson G., Jacob M., Price A.B., Macpherson A., Mahmod T., Scott D., Wrigglesworth J.M., Bjarnason I. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997, 41:344-353.
34. Somasundaram S., Sigthorsson G., Simpson R.J., Watts J., Jacob M., Tavares I.A., Rafi S., Roseth A., Foster R., Price A.B., Wrigglesworth J.M., Bjarnason I. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment. Pharmacol. Ther. 2000, 14:639-650.
35. Sukardi H., Chng H.T., Chan E.C., Gong Z., Lam S.H. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. Expert Opin. Drug Metab. Toxicol. 2011, 7:579-589.
36. Tarazi E.M., Harter J.G., Zimmerman H.J., Ishak K.G., Eaton R.A. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993, 104:569-574.
37. Traversa G., Bianchi C., Da Cas R., Abraha I., Menniti-Ippolito F., Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003, 327:18-22.
38. van Puijenbroek E.P., Bate A., Leufkens H.G., Lindquist M., Orre R., Egberts A.C. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 2002, 11:3-10.
39. Will Y., Hynes J., Ogurtsov V.I., Papkovsky D.B. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat. Protoc. 2006, 1:2563-2572.
40. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105.
41. Xu J.J., Dunn M.C., Smith A.R., Tien E.S. Assessment of hepatotoxicity potential of drug candidate molecules including kinase inhibitors by hepatocyte imaging assay technology and bile flux imaging assay technology. Methods Mol. Biol. 2012, 795:83-107.
42. Zimmerman H.J. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver 1999, Lippincott Williams & Wilkins, Philadelphia, PA, USA.